Table 2.
Pattern of drug resistance among previously treated tuberculosis patients at the Korle-Bu Teaching Hospital Chest Clinic, Accra
| Characteristic | Number | Percent |
|---|---|---|
| First-line drug resistance (n = 112) | ||
| Pan-sensitive | 53 | 47.3% |
| Any resistance | ||
| S | 43 | 38.4% |
| H | 44 | 39.3% |
| R | 34 | 30.4% |
| E | 8 | 7.1% |
| Mono resistance | ||
| S | 12 | 10.7% |
| H | 6 | 5.4% |
| R | 1 | 0.9% |
| E | 0 | 0.0% |
| Poly resistance/Other | ||
| HS | 6 | 5.4% |
| RS | 2 | 1.8% |
| HE | 1 | 0.9% |
| (HR) MDR TB | 31 | 27.7% |
| MDR TB (n = 31) | ||
| HR only | 7 | 6.3% |
| HRS | 17 | 15.2% |
| HRE | 1 | 0.9% |
| HRES | 6 | 5.4% |
| Second-line drug resistance (n = 31) | ||
| Pre-XDR TBa | 11 | 35.5% |
| Ofloxacin | 3 | 9.7% |
| Capreomycin | 8 | 25.8% |
| Kanamycin | 1b | 3.2% |
| Ethionamide | 10 | 32.3% |
S streptomycin, H isoniazid, R rifampin, E ethambutol, MDR-TB multidrug resistant tuberculosis, pre-XDR pre-extensively drug resistant tuberculosis
aPre-XDR TB is resistance to either a second-line injectable (kanamycin, capreomycin) or a fluoroquinolone (ofloxacin), but not both
bone patient had resistance to both capreomycin and kanamycin, but not ofloxacin